Equities

BioSig Technologies Inc

BSGM:NAQ

BioSig Technologies Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.70
  • Today's Change-0.08 / -4.49%
  • Shares traded63.27k
  • 1 Year change-87.50%
  • Beta0.7960
Data delayed at least 15 minutes, as of May 03 2024 16:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioSig Technologies, Inc. is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. The Company’s product, the PURE EP Platform, a non-invasive class II device, provides real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures. Integrating with existing systems in the EP lab, PURE EP is designed to pinpoint even the complex signals to maximize procedural success and efficiency. The PURE EP System is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise from other equipment, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP is a signal processing platform that combines advanced hardware and software to address known challenges associated to signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time.

  • Revenue in USD (TTM)18.00k
  • Net income in USD-29.05m
  • Incorporated2011
  • Employees4.00
  • Location
    BioSig Technologies Inc55 Greens Farms RoadWESTPORT 06880United StatesUSA
  • Phone+1 (203) 409-5444
  • Fax+1 (302) 645-1280
  • Websitehttps://www.biosig.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PetVivo Holdings Inc1.05m-10.63m13.92m25.00--13.84--13.31-0.8694-0.86940.08420.060.33751.212.0441,841.60-343.12-209.90-715.73-504.6451.4120.27-1,016.55-2,297.210.6169-2,268.840.1392--693.46260.32-73.83--51.73--
STRATA Skin Sciences Inc33.36m-10.83m14.02m99.00--1.11--0.4204-0.3101-0.31010.95530.36190.70765.177.49336,949.50-22.97-11.48-31.53-16.5555.3461.28-32.47-17.701.06-4.430.5425---7.752.24-95.17--23.29--
QT Imaging Holdings Inc0.00-4.02m16.85m----0.7752-----0.3999-0.39990.001.010.00-------12.32---16.60--------------0.3042-------45.07------
REMSleep Holdings Inc203.73k-1.78m17.03m6.00--18.44--83.58-0.0012-0.00120.00010.00060.08921.6619.66---77.85-152.40-92.09-317.98-371.44---872.65-2,317.523.18-353.980.00---36.48--12.13--28.26--
Meihua International Medical Tech Co Ltd97.10m11.63m17.58m617.001.420.1131.460.1810.48560.48564.066.110.578846.661.31157,372.606.9112.268.1315.0534.1938.1411.9415.475.21--0.04750.00-6.055.1086.22-5.56-9.16--
Dalrada Financial Corporation31.32m-22.48m17.63m0.00------0.5627-0.2547-0.25470.3552-0.03341.229.255.22---90.33-80.63-513.68--25.0139.23-74.24-63.940.6296-25.241.61--54.35---43.94------
Orgenesis Inc530.00k-55.36m18.65m146.00------35.18-1.97-1.970.0184-0.65830.0181.230.02923,630.14-123.09---313.24---1,080.19---12,248.68--0.2464-16.1816.82---98.53-50.94-271.82---17.71--
BioSig Technologies Inc18.00k-29.05m19.93m4.00------1,107.38-4.08-4.080.0025-0.32220.00610.001.094,500.00-971.23-269.73---363.1172.22---159,388.90-24,485.730.1152-------93.71---6.52---9.58--
PAVmed Inc2.45m-66.27m21.13m107.00------8.62-9.24-9.240.3392-6.280.0563--62.8722,915.89-182.01-154.56---1,152.82-161.87---3,232.63-8,764.890.447-10.582.19--550.40--25.76--55.51--
Neuraxis Inc2.46m-14.63m21.76m17.00------8.85-3.78-3.780.5432------------------87.67---594.57-----23.75-----8.37---163.78------
Ekso Bionics Holdings Inc17.91m-14.24m23.35m70.00--1.66--1.30-0.9685-0.96851.200.77650.54231.653.38255,900.00-43.11-43.63-57.86-57.6750.4151.93-79.48-104.242.11-34.630.2937--41.5710.03-0.7825--3.69--
Agape ATP Corp1.43m-2.10m23.41m21.00--5.36--16.36-0.0276-0.02760.01890.05680.335310.5028.0968,147.14-49.44---68.03--65.44---147.44--4.79--0.0179---22.92---24.61------
SANUWAVE Health Inc20.40m-25.81m26.23m31.00------1.29-0.0455-0.04550.0257-0.03790.96473.165.56657,967.80-122.05-136.54----70.4169.13-126.52-189.600.1055-0.0214----21.8461.61-150.72------
Data as of May 03 2024. Currency figures normalised to BioSig Technologies Inc's reporting currency: US Dollar USD

Institutional shareholders

11.59%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 31 Dec 2023560.00k6.00%
The Vanguard Group, Inc.as of 31 Dec 2023238.39k2.55%
PFG Investments LLCas of 31 Mar 2024106.15k1.14%
BlackRock Fund Advisorsas of 31 Dec 202359.92k0.64%
Geode Capital Management LLCas of 31 Dec 202356.62k0.61%
SSgA Funds Management, Inc.as of 31 Dec 202317.74k0.19%
Commonwealth Equity Services LLCas of 31 Dec 202312.57k0.14%
Truist Bank (Private Banking)as of 31 Dec 202311.23k0.12%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 202311.09k0.12%
Citadel Securities LLCas of 31 Dec 20237.73k0.08%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.